Volume 94 Issue 1 | p. 9 | News of The Week
Issue Date: January 4, 2016

Gene Editing: Bayer and Crispr Therapeutics form CRISPR/Cas9 technology pact

Department: Business
News Channels: Biological SCENE
Keywords: pharmaceuticals, biotech, gene editing, CRISPR

Bayer and Crispr Therapeutics have established a joint venture to use CRISPR/Cas9 gene-editing technology to develop therapies to treat blood disorders, blindness, and congenital heart disease. Bayer will sink at least $300 million into R&D over the five-year pact and is taking a minority stake worth $35 million in CRISPR Therapeutics.

Like the “find and replace” function in Microsoft Word, the CRISPR/Cas9 system enables researchers to precisely snip out problematic stretches of DNA and swap . . .

To view the rest of this content, please log in with your ACS ID.



 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society